The significance of BLCA-4 in early diagnosis and postoperative monitoring of tumor recurrence in patients with bladder cancer

Abstract

Objective To investigate the clinical significance of urinary bladder cancer specific nuclear matrix protein-4 (BLCA-4) for the diagnosis of bladder cancer and postoperative monitoring of bladder cancer recurrence. Methods From February 2012 to January 2016 in our hospital 87 patients with bladder cancer pathology confirmed cases (bladder cancer group), 30 patients with urinary tract benign lesions (benign group) and 30 cases of normal healthy people (control group), and the level of BLCA-4 in urine of three groups and recurrence 24 months postoperatively were detected. One month, 6 months and 24 months before and after surgery, the levels of urinary BLCA-4 were compared. Results Preoperative urine BLCA-4 level of bladder cancer group was significantly higher than that of the benign group and healthy group, the difference was statistically significant (P<0.05). The level of BLCA-4 in benign lesion in urine was significantly higher than that of healthy group (P<0.05). The sensitivity of urine BLCA-4 level in the differential diagnosis of bladder cancer was 95.00% and the specificity was 96.67%, the rate of misdiagnosis 5.00%, the misdiagnosis rate was 3.33%, the area under the ROC curve of AUC value consistency was 0.949, urine BLCA-4 level in the differential diagnosis of bladder cancer and the pathological results was 0.916. The recurrence of postoperative BLCA-4 level 6 months and 24 months in the urine was significantly higher than that for the non-recurrence group (P<0.05). Conclusions BLCA-4 level of urine in the differential diagnosis of bladder cancer has a certain clinical value, postoperative monitoring is conducive to the early detection of postoperative recurrence. Key words: Urinary Bladder Neoplasms; Nuclear Matrix-Associated Proteins; Neoplasm Recurrence, Local